Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAPA-pulsed DC vaccine consolidation in hematologic malignancies
NCT02709993Phase 2Withdrawn
- Sponsor
- Kiromic BioPharma, Inc.
- Start
- Jul 2017
- Primary completion
- Oct 2020
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of KiroVax in multiple myeloma (MM), Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL) and 4 more, sponsored by Kiromic BioPharma, Inc. Primary endpoint: Number of adverse events due to administration of TAPA-pulse DC vaccine. Planned start Jul 2017; status: withdrawn.
02
Drugs
KiroVax
03
Conditions
multiple myeloma (MM)Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)chronic myeloid leukemia (CML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT02709993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02709993.